Background: The recent availability of direct acting antiviral drugs (DAAs) has drastically changed hepatitis C virus (HCV) treatment scenarios, due to the exceedingly high rates of sustained virological response (SVR) and excellent tolerability allowing for treatment at all disease stages. Methods: A panel of Italian experts was convened twice, in November 2016 and January 2017, to provide further support on some open issues and provide guidance for personalized HCV care, also in light of forthcoming regimens. Results and conclusions: Treatment recommendations issued by international and national liver societies to guide clinicians in the management of HCV infection are constantly updated due to accumulating new data. Such recommendations may not be applicable to all healthcare settings for a variety of reasons. Moreover, some gaps still remain and the spectrum of patients to be treated is also evolving.

Current and future challenges in HCV: insights from an Italian experts panel / Andreoni, Massimo; Babudieri, Sergio; Bruno, Savino; Colombo, Massimo; Zignego, Anna L.; Di Marco, Vito; Di Perri, Giovanni; Perno, Carlo F.; Puoti, Massimo; Taliani, Gloria; Villa, Erica; Craxã¬, Antonio. - In: INFECTION. - ISSN 0300-8126. - 46:2(2018), pp. 1-147. [10.1007/s15010-017-1093-1]

Current and future challenges in HCV: insights from an Italian experts panel

Taliani, Gloria;
2018

Abstract

Background: The recent availability of direct acting antiviral drugs (DAAs) has drastically changed hepatitis C virus (HCV) treatment scenarios, due to the exceedingly high rates of sustained virological response (SVR) and excellent tolerability allowing for treatment at all disease stages. Methods: A panel of Italian experts was convened twice, in November 2016 and January 2017, to provide further support on some open issues and provide guidance for personalized HCV care, also in light of forthcoming regimens. Results and conclusions: Treatment recommendations issued by international and national liver societies to guide clinicians in the management of HCV infection are constantly updated due to accumulating new data. Such recommendations may not be applicable to all healthcare settings for a variety of reasons. Moreover, some gaps still remain and the spectrum of patients to be treated is also evolving.
2018
Comorbidities; DAAs; HCV; Treatment; Microbiology (medical); Infectious Diseases
01 Pubblicazione su rivista::01a Articolo in rivista
Current and future challenges in HCV: insights from an Italian experts panel / Andreoni, Massimo; Babudieri, Sergio; Bruno, Savino; Colombo, Massimo; Zignego, Anna L.; Di Marco, Vito; Di Perri, Giovanni; Perno, Carlo F.; Puoti, Massimo; Taliani, Gloria; Villa, Erica; Craxã¬, Antonio. - In: INFECTION. - ISSN 0300-8126. - 46:2(2018), pp. 1-147. [10.1007/s15010-017-1093-1]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1040422
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 2
social impact